Redhill Biopharma (NASDAQ:RDHL) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Redhill Biopharma beat estimated earnings by 84.85%, reporting an EPS of $-0.05 versus an estimate of $-0.33.
Revenue was up $610.00 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.29 which was followed by a 6.85% drop in the share price the next day.
Here's a look at Redhill Biopharma's past performance:
Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
---|---|---|---|---|
EPS Estimate | -0.21 | -0.12 | -0.34 | -0.24 |
EPS Actual | -0.50 | -0.06 | -0.05 | -0.07 |
Revenue Estimate | 24.52M | 25.02M | 22.70M | 26.03M |
Revenue Actual | 21.61M | 21.50M | 20.57M | 21.46M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.